Home
Current projects
Methods for valuing health states
Blog
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Direct to consumer genetic tests
Value of research
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Subscribe
Healthanomics
A collection of work and information about decision making in health
27 posts:
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis
03.11.2009
Tagged as:
Paper
More details →
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis
01.11.2009
Tagged as:
Paper
More details →
Development of a population-based microsimulation model of osteoarthritis in Canada
23.10.2009
Tagged as:
Paper
More details →
The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis
24.09.2009
Tagged as:
Paper
More details →
Why do patients with inflammatory arthritis often score states “worse than death” on the EQ-5D? An Investigation of the EQ-5D classification system
01.09.2009
Tagged as:
Paper
More details →
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis
28.04.2009
Tagged as:
Paper
More details →
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
01.04.2009
Tagged as:
Paper
More details →
Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis
01.04.2009
Tagged as:
Paper
More details →
The economics of treatment in early rheumatoid arthritis
01.02.2009
Tagged as:
Paper
More details →
Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
01.12.2008
Tagged as:
Paper
More details →
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis
01.09.2008
Tagged as:
Paper
More details →
Health state utility values: A description of their development and application for rheumatic diseases
01.07.2008
Tagged as:
Paper
More details →
Biologic Drugs for Rheumatoid Arthritis in the Medicare Program
01.04.2008
Tagged as:
Paper
More details →
The Validity and Responsiveness of Generic Utility Measures in Rheumatoid Arthritis: A Review
01.04.2008
Tagged as:
Paper
More details →
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
01.02.2008
Tagged as:
Paper
More details →
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis
15.08.2007
Tagged as:
Paper
More details →
Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
01.08.2007
Tagged as:
Paper
More details →
The efficacy of inhibiting tumour necrosis factor {alpha} and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
01.07.2007
Tagged as:
Paper
More details →
Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis
03.05.2007
Tagged as:
Paper
More details →
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
15.03.2007
Tagged as:
Paper
More details →
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis
01.08.2006
Tagged as:
Paper
More details →
A prognostic model for functional outcome in early rheumatoid arthritis
01.08.2006
Tagged as:
Paper
More details →
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor-[alpha] Antagonists
01.12.2005
Tagged as:
Paper
More details →
A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis
05.10.2005
Tagged as:
Paper
More details →
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
01.07.2005
Tagged as:
Paper
More details →
The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden
01.07.2005
Tagged as:
Paper
More details →
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
01.01.2004
Tagged as:
Paper
More details →
Display multiple categories by selecting below
Disease Areas
Arthritis
Cancer
Dermatology
HIV
Obesity
Opthalmology
Publications
Papers
Presentations
Research methods
Economic evaluation
Epidemiology
Meta analysis
Other
Outcome measurement and valuation
Productivity
Year
2001
2004
2005
2006
2007
2008
2009
2010
Most important contributions
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis
Impact of the recall period on measuring health utilities for acute events
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
Using a discrete choice experiment to estimate societal health state utility values
Translator